
Uncategorized - February 20, 2015
Positive Phase 2 Trial for Oral Insulin
Novo Nordisk has successfully completed the phase 2 trial for OG217SC, an oral formulation of the long-acting GLP-1 analogue semaglutidea, a form of oral insulin, sending its stock shares climbing. Semaglutide appeared to have “a safe and well-tolerated profile,” according to Novo Nordisk. The 26-week trial included tests of dose range, escalation, efficacy and safety of once-daily doses […]